How Do They Biopsy a Lung? Methods and What to Expect

Lung biopsies are performed using one of three broad approaches: a needle inserted through the chest wall under CT guidance, a thin scope threaded down through the airways, or a surgical procedure that accesses lung tissue directly. Which method your doctor recommends depends on where the suspicious spot sits inside the lung, how large it is, what information the pathologist needs, and your overall health. Most lung biopsies are outpatient or short-stay procedures, but the experience varies meaningfully across methods, and so do the risks.

CT-Guided Needle Biopsy Through the Chest Wall

The most common way to sample a lung nodule near the outer edge of the lung is a percutaneous (through-the-skin) needle biopsy guided by a CT scanner. You lie on the scanner table, and after numbing a small area on your back or side with local anesthetic, a radiologist advances a thin needle between your ribs and into the target. The CT images update in near real-time, allowing the radiologist to steer the needle tip precisely into the lesion. The whole procedure typically takes 30 to 60 minutes, and you’re awake the entire time.

Two needle types are used. Fine-needle aspiration uses a very thin needle to suction out individual cells, while a core needle biopsy uses a slightly thicker needle with a spring-loaded cutting mechanism that removes a small cylinder of tissue. Core needle biopsies tend to provide better samples: one meta-analysis found that core needles had a sample adequacy rate of about 96% compared with roughly 86% for fine-needle aspiration.¹ Core needles also give the pathologist a piece of intact tissue architecture rather than a smear of loose cells, which matters when the lab needs to determine the exact subtype of a tumor or run molecular tests on it.

Overall diagnostic accuracy for CT-guided needle biopsy is high. A study of nodules smaller than 2 cm reported accuracy of about 92%, with larger lesions performing even better.² The main factors that lower accuracy are very small lesion size and bleeding around the lesion during the procedure, which can obscure the target. Systematic reviews comparing the two needle types show core biopsies reaching sensitivity in the range of 86–97% and fine-needle aspiration in the range of 81–91%.³

What a CT-Guided Biopsy Feels Like

A prospective study that asked patients directly about their experience found that about 20% described the procedure as painful, while the rest reported little or no pain beyond the initial sting of the local anesthetic.⁴ Around 29% felt short of breath immediately after, and about 12% coughed up a small amount of blood, usually less than a tablespoonful. Most patients describe a pressure sensation and an urge to cough when the needle reaches the lung. You’ll be asked to hold your breath briefly at specific moments so the lung stays still during needle advancement.

After the biopsy, you typically stay in recovery for a few hours while the medical team monitors you and takes a follow-up chest X-ray to check for complications. If everything looks clear, you go home the same day with instructions to avoid heavy lifting and strenuous activity for a day or two.

Bronchoscopic Biopsy Through the Airways

Instead of going through the chest wall, bronchoscopic biopsies reach the lung from the inside. A pulmonologist passes a flexible bronchoscope — a thin tube with a camera and a working channel — through your nose or mouth, down the trachea, and into the airways. Tissue samples are collected using tiny forceps, brushes, or needles fed through the scope. Bronchoscopy is generally preferred when the abnormality sits near a central airway or when the goal is to sample lymph nodes in the middle of the chest for cancer staging.

For lymph node sampling, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has largely replaced more invasive staging procedures. The scope carries a small ultrasound probe at its tip, letting the pulmonologist see lymph nodes through the airway wall and guide a needle directly into them. In a large series of over 500 patients, EBUS-TBNA achieved a sensitivity of 94% with no complications.⁵ A head-to-head trial comparing EBUS-TBNA with mediastinoscopy — the traditional surgical approach to lymph node staging — found no significant difference in accuracy between the two methods.⁶ That’s a significant shift: patients can get the same staging information without an incision in the neck and without general anesthesia.

For peripheral lung nodules — small spots that sit far out in the lung where the airways become too narrow for a standard scope to reach — conventional bronchoscopy has historically been less reliable. This is where newer navigation technologies come in.

Robotic Bronchoscopy and Navigation Platforms

Robotic bronchoscopy is one of the more exciting recent developments in lung biopsy. These systems use either electromagnetic navigation or shape-sensing technology to steer an ultra-thin catheter deep into the lung’s branching airways, reaching nodules that were previously accessible only by a needle through the chest wall or surgery.⁷ One shape-sensing system uses a flexible 3.5-mm catheter that articulates in all directions, guided by a three-dimensional map of the patient’s airways reconstructed from a pre-procedure CT scan.⁸

The advantage of robotic bronchoscopy over a CT-guided needle is the route: because the catheter travels inside the airways, it avoids puncturing the outer lining of the lung, which substantially lowers the risk of pneumothorax. A study combining robotic bronchoscopy with cryobiopsy — freezing a tiny probe tip to pull off a tissue sample — found that the combination was safe and provided more diagnostic tissue than standard needle aspirates or forceps biopsies.⁹ These systems are still relatively new and available mainly at larger medical centers, but they’re expanding quickly.

Transbronchial Cryobiopsy for Diffuse Lung Disease

Not every lung biopsy is hunting for a nodule. When doctors suspect an interstitial lung disease — a category of conditions that affects the tissue between the air sacs — they often need a broader sample of lung tissue to see the pattern of scarring or inflammation. Traditionally, that meant surgery. Transbronchial cryobiopsy has emerged as a less invasive alternative.

The technique works through a standard bronchoscope. A thin cryoprobe is advanced into a peripheral airway, rapidly cooled to freeze the surrounding tissue, then pulled back with the frozen tissue attached. The resulting sample is considerably larger and better preserved than what conventional forceps can obtain. Reported diagnostic yield for interstitial lung disease is typically in the range of 70–85%.¹⁰ A comparative study found that cryobiopsy achieved a diagnostic yield of 85% versus 63% for conventional transbronchial forceps biopsy.¹¹

European Respiratory Society guidelines acknowledge that cryobiopsy provides important diagnostic information for undiagnosed interstitial lung disease, though its diagnostic yield remains lower than surgical lung biopsy. The trade-off is that cryobiopsy causes fewer serious complications and a shorter hospital stay.¹² For many patients, especially those who are poor candidates for general anesthesia, cryobiopsy offers a reasonable middle ground between a forceps biopsy that might not get enough tissue and full surgery.

Surgical Lung Biopsy

When less invasive methods fail to produce a diagnosis, or when a larger tissue sample is essential, surgery becomes the answer. The most common surgical approach today is video-assisted thoracoscopic surgery, or VATS. The surgeon makes one to three small incisions between the ribs, inserts a camera and instruments, and removes a wedge-shaped piece of lung tissue. A 15-year analysis of over 740 lung VATS procedures documented this as a well-established technique for both diagnostic biopsies and therapeutic resections.¹³ Some centers have refined this further to a single-incision approach, requiring just one 2–2.5 cm cut.¹⁴

Surgical biopsy is performed under general anesthesia, though some centers have explored using regional anesthesia with sedation as an alternative in selected patients.¹⁵ Recovery involves a chest tube that typically stays in for one to a few days to drain air and fluid, followed by a hospital stay that ranges from one to several days depending on the extent of the procedure and how the lung re-expands. Compared with needle or bronchoscopic biopsies, surgical biopsy provides the most tissue and the highest diagnostic certainty, but it carries greater risks of pain, infection, and longer recovery.

Complications and Risk Factors

Every lung biopsy method carries some risk, but the most talked-about complication of CT-guided needle biopsy is pneumothorax — a partial collapse of the lung caused by air leaking through the puncture site. A large systematic review and meta-analysis found that about 26% of patients develop some degree of pneumothorax after a CT-guided biopsy, though most cases are small and resolve on their own.¹⁶ Only about 5–7% of patients need a chest tube to re-expand the lung, and a separate review placed that rate at 4–6%.¹⁷

The distance the needle has to travel through normal lung tissue to reach the target matters. When the lesion sits more than 3 cm from the outer lung surface, the risk of pneumothorax climbs substantially.² Emphysema, which leaves the lung tissue fragile and full of air pockets, also raises the risk. Techniques like rolling the patient onto the puncture side immediately after the biopsy, or injecting a blood patch into the needle tract as the needle is withdrawn, can help reduce pneumothorax rates.

Bleeding inside the lung is the other main complication. One large retrospective study of over 1,000 CT-guided biopsies found that about 31% of patients had some degree of bleeding visible on the scan, though most of it was minor — only about 7% experienced higher-grade hemorrhage, and about 3% coughed up blood.¹⁸ Smaller lesions, deeper lesions, and lesions in the lower lobes tend to bleed more. Another study found overall hemorrhage in about 43% of cases, though again, much of it was low-grade and self-limited.¹⁹ Protective factors for reducing serious bleeding include preoperative breathing exercises and using semiautomatic cutting needles with a coaxial technique.²⁰

Rare but serious complications include air embolism, where air enters a pulmonary vein and travels to the brain or heart. The true incidence is likely underestimated because not all cases cause obvious symptoms.²¹ It remains extremely uncommon, and radiologists take precautions — such as never advancing the needle with the inner stylet removed — to minimize the risk.

Preparing for a Lung Biopsy

If you’re on blood-thinning medications, your doctor will likely ask you to stop some of them before the procedure. Aspirin appears to be safe enough to continue through a bronchoscopy, but stronger antiplatelet drugs like clopidogrel are generally held for about seven days beforehand. Anticoagulants such as warfarin or newer direct oral anticoagulants also need to be stopped, with the timing depending on the specific drug and your risk of blood clots.²² Some patients at high clot risk may need a bridging strategy with a shorter-acting blood thinner until the procedure.

For CT-guided biopsies, you’ll usually be told not to eat or drink for several hours beforehand, even though you won’t be under general anesthesia, in case the procedure needs to be converted to something more involved. You’ll change into a hospital gown, and an IV line is placed for fluids and any sedation if needed. Bronchoscopy typically involves moderate sedation — enough that you’re relaxed and unlikely to remember much, but you can still follow breathing instructions. Surgical biopsy requires a full anesthetic workup.

What Happens to the Tissue After It’s Removed

The biopsy itself is only half the process. Once the tissue reaches the pathology lab, a chain of analyses begins that drives every treatment decision. Pathologists examine thin slices under a microscope, looking at cell shape, arrangement, and growth pattern. For suspected lung cancer, they need to determine whether it’s small cell or non-small cell, and if non-small cell, whether it’s adenocarcinoma, squamous cell carcinoma, or another subtype. A limited panel of immunohistochemical stains — proteins that bind to specific markers on tumor cells — can make this distinction reliably, even on a small biopsy specimen.²³

Some centers now use rapid on-site evaluation (ROSE), where a cytopathologist examines the sample immediately during the biopsy procedure. If the initial sample isn’t adequate, the proceduralist can take additional passes before the patient leaves the table. One study found that ROSE agreed with the final pathology diagnosis in about 94% of cases.²⁴ This real-time feedback helps avoid the frustrating scenario of an inconclusive biopsy that requires a repeat procedure.

Beyond identifying the cancer type, the tissue increasingly needs to be tested for specific genetic mutations that determine which targeted therapies or immunotherapies might work. The number of actionable biomarkers in non-small cell lung cancer has expanded rapidly, and current guidelines call for simultaneous multi-gene testing using next-generation sequencing rather than testing for mutations one at a time, which can exhaust the limited tissue from a small biopsy.²⁵ This is one reason why core needle biopsies and cryobiopsies, which yield larger specimens, have become preferred — there’s simply more tissue to work with when the lab needs to run a battery of molecular tests.

Liquid Biopsy as a Complement

A blood draw is far simpler than any lung biopsy, and liquid biopsy — analyzing tumor DNA that has shed into the bloodstream — is gaining traction as a tool for guiding treatment in advanced lung cancer. One study found that for guideline-recommended biomarkers, liquid biopsy results were 95–100% concordant with tissue biopsy, with faster turnaround time and similar outcomes.²⁶

That doesn’t mean liquid biopsy is ready to replace tissue sampling. A comprehensive systematic review found that the agreement between liquid and tissue results varied by gene, with positive percent agreement rates ranging from about 54% to 68% depending on the mutation being tested.²⁷ When a liquid biopsy detects a mutation, you can trust the result. But when it comes back negative, the mutation could still be present — the tumor may simply not be shedding enough DNA into the blood. This is why many oncologists use liquid biopsy as a first-line screen to get results quickly, then follow up with tissue biopsy if the blood test doesn’t find a targetable mutation. In patients who are too sick for a tissue biopsy, or when the tumor is in a difficult-to-reach location, liquid biopsy provides a valuable fallback.

How Doctors Choose the Right Method

The decision tree for lung biopsy is less about which method is “best” in the abstract and more about what fits the clinical picture. Lesion location is usually the first consideration. Nodules near the chest wall are natural candidates for CT-guided needle biopsy. Masses sitting along a major airway, or enlarged lymph nodes in the center of the chest, are best approached through bronchoscopy with EBUS. Deep peripheral nodules that are hard to reach by needle without a long and risky path through normal lung tissue may now be candidates for robotic bronchoscopy. Diffuse lung disease that requires a pattern-based diagnosis needs either cryobiopsy or surgical biopsy for adequate tissue.

Patient factors matter too. Someone with severe emphysema faces a higher pneumothorax risk from a needle biopsy, which might push toward a bronchoscopic approach. Someone on blood thinners that can’t safely be stopped might need a method with a lower bleeding risk. Patients with poor lung function may not tolerate general anesthesia well, ruling out surgery in favor of a sedation-based procedure. And the diagnostic question itself plays a role: if the oncologist needs enough tissue for comprehensive molecular profiling, a core needle or cryobiopsy may be preferred over fine-needle aspiration, which sometimes delivers too few cells for the full panel of tests.

Your doctor might also weigh how many procedures are likely to be needed. A CT-guided needle biopsy is highly accurate for peripheral nodules, but if the first attempt is inconclusive, repeating it means another trip through the chest wall with cumulative pneumothorax risk. Bronchoscopic methods with ROSE can adjust on the fly. Surgical biopsy almost always gets a definitive answer on the first attempt, but at a higher upfront cost in terms of recovery. There’s rarely a single “right” answer; the choice reflects a negotiation between accuracy, safety, tissue yield, and what your body can handle.

When a Biopsy Comes Back Inconclusive

Even with high-accuracy methods, not every biopsy produces a clear answer. Sometimes the sample contains only blood or normal lung tissue instead of the target lesion. Sometimes the cells are abnormal but not clearly cancerous, leaving the pathologist unable to commit to a diagnosis. When that happens, the team weighs the likelihood that something serious is present against the risks of repeating the procedure. A second biopsy using the same or a different method is common. In some cases, doctors opt for close surveillance with repeat imaging instead, watching whether a nodule grows before deciding on another invasive step. And occasionally, the uncertainty is great enough that surgical removal of the nodule serves as both the diagnostic and therapeutic move — if it turns out to be cancer, it’s already been taken out.